Cardiac Lesion Found in 2-Month-Old Child

Poll

A 2-month-old child with a history of tuberous sclerosis presents with a cardiac lesion. After a biopsy is performed, what is your diagnosis?

A 2-month-old child with a history of tuberous sclerosis presents with a cardiac lesion. According to the pathology slide below, what is your diagnosis?

What is your diagnosis?

A. Gaucher’s disease
B. Fabry disease
C. Rhabdomyoma
D. Syphilis
Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
young person with cancer
uterus
Related Content
CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

Tim Cortese
May 23rd 2025
Article

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.

FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma

FDA Grants RMAT Designation to CAR T Therapy for Incurable Pediatric Glioma

Tim Cortese
May 16th 2025
Article

The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

Russ Conroy
February 14th 2025
Article

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.

FDA Approves Remestemcel-L in Pediatric SR-aGVHD

Russ Conroy
December 18th 2024
Article

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications

Russ Conroy
October 29th 2024
Article

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.

Opaganib Earns FDA Orphan Drug Status in Neuroblastoma

Russ Conroy
August 27th 2024
Article

Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.